Literature DB >> 1703989

Reduced activity of DAF on complement enzymes bound to alternative pathway activators. Similarity with Factor H.

M K Pangburn1.   

Abstract

Attachment of C3b to activators of the alternative pathway of complement results in a decrease in regulatory activity expressed by Factor H. Decay-accelerating factor (DAF) and Factor H were found to exhibit quantitatively similar decreases in regulatory activity toward the C3 convertase (C3b,Bb) bound to activators, such as zymosan (Zym) and rabbit erythrocytes (ER), compared to non-activators, such as sheep (ES) and bovine (EB) erythrocytes. Purified DAF and Factor H, in 0.1% NP-40, were assayed by measuring the amount required to release 50% of the radiolabelled Bb in 10 min from C3b,Bb on Zym or cross-linked erythrocytes. The relative effectiveness (i.e. the restriction index, RI) of DAF for accelerating the decay of C3b,Bb on the various particles was: ES (1.0), ER (0.04) and Zym (0.03). The RI for Factor H was: ES (1.0), ER (0.04) and Zym (0.07). The rate of decay of C3b,Bb induced by DAF and Factor H showed similar restriction. The results suggest that the regulatory properties of DAF are reduced if the cells on which it resides become activators of the alternative pathway as a result of transformation, virus infection or surface alteration. These findings may explain reports of dysfunctional DAF on alternative pathway-activating cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1703989      PMCID: PMC1384886     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  12 in total

1.  Production of mouse monoclonal antibodies that detect distinct neoantigenic epitopes on bound C3b and iC3b but not on the corresponding soluble fragments.

Authors:  B Nilsson; K E Svensson; P Borwell; U R Nilsson
Journal:  Mol Immunol       Date:  1987-05       Impact factor: 4.407

2.  Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells.

Authors:  M K Pangburn; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1978-05       Impact factor: 11.205

3.  Analysis of recognition in the alternative pathway of complement. Effect of polysaccharide size.

Authors:  M K Pangburn
Journal:  J Immunol       Date:  1989-04-15       Impact factor: 5.422

4.  Raji cell injury and subsequent lysis by the purified cytolytic alternative pathway of human complement.

Authors:  R D Schreiber; M K Pangburn; R G Medicus; H J Müller-Eberhard
Journal:  Clin Immunol Immunopathol       Date:  1980-03

5.  Activation of the alternative complement pathway: recognition of surface structures on activators by bound C3b.

Authors:  M K Pangburn; D C Morrison; R D Schreiber; H J Müller-Eberhard
Journal:  J Immunol       Date:  1980-02       Impact factor: 5.422

6.  Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H.

Authors:  S Meri; M K Pangburn
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

7.  Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor.

Authors:  A Nicholson-Weller; J P March; S I Rosenfeld; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1983-08       Impact factor: 11.205

8.  Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria.

Authors:  M K Pangburn; R D Schreiber; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

9.  Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms.

Authors:  D T Fearon; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1977-04       Impact factor: 11.205

10.  Lysis of measles virus-infected cells by the purified cytolytic alternative complement pathway and antibody.

Authors:  J G Patrick Sissons; R D Schreiber; L H Perrin; N R Cooper; H J Müller-Eberhard; M B Oldstone
Journal:  J Exp Med       Date:  1979-09-19       Impact factor: 14.307

View more
  4 in total

1.  Location of the complement factor H binding site on streptococcal M6 protein.

Authors:  V A Fischetti; R D Horstmann; V Pancholi
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

2.  Complementary recognition of alternative pathway activators by decay-accelerating factor and factor H.

Authors:  D Kraus; M E Medof; C Mold
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

3.  Mapping of the C3b-binding site of CR1 and construction of a (CR1)2-F(ab')2 chimeric complement inhibitor.

Authors:  K R Kalli; P H Hsu; T J Bartow; J M Ahearn; A K Matsumoto; L B Klickstein; D T Fearon
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

Review 4.  Therapeutic uses of recombinant complement protein inhibitors.

Authors:  K R Kalli; P Hsu; D T Fearon
Journal:  Springer Semin Immunopathol       Date:  1994
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.